Lauren George, MD
Gastroenterology · Washington, DCNPI 1023384948
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $23,700 of the $31,619 with a category attached, or 75.0%. Johnson & Johnson accounts for 72.6% of it on its own, with 27 other manufacturers making up the rest.
Across 228 payments — averaging $138.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$23K
- E.r. Squibb & Sons, L.L.C.$4K
- AbbVie$1K
- Bristol Myers Squibb$1K
- Takeda Pharmaceuticals U.S.A., Inc.$740
- Pfizer$663
- plus $1K from 22 others
Across 8 payments — averaging $1225.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$10K
What the payments were for
- Consulting fees$23,70075%
- Travel & lodging$9563%
- Food & beverage$6,93222%
- Education$310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 64 | $22,941 |
| E.r. Squibb & Sons, L.L.C. | 2 | $3,544 |
| AbbVie | 32 | $1,206 |
| Bristol Myers Squibb | 22 | $1,028 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $740 |
| Pfizer | 28 | $663 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $198 |
| Medtronic | 1 | $146 |
| Intercept Pharmaceuticals, Inc. | 6 | $134 |
| Janssen Research & Development, LLC | 1 | $122 |
| Mallinckrodt Hospital Products Inc. | 3 | $97 |
| Celltrion USA Inc. | 3 | $95 |
| Shionogi Inc | 4 | $76 |
| Madrigal Pharmaceuticals | 2 | $75 |
| Dynavax Technologies Corporation | 4 | $69 |
| Amgen | 2 | $58 |
| Phathom Pharmaceuticals, Inc. | 5 | $56 |
| Braintree Laboratories, Inc. | 2 | $50 |
| Ardelyx, Inc. | 2 | $42 |
| Janssen Scientific Affairs, LLC | 1 | $41 |
| Lilly USA, LLC | 2 | $38 |
| QOL Medical, LLC | 1 | $36 |
| Novo Nordisk | 2 | $35 |
| Ferring Pharmaceuticals Inc. | 3 | $34 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Boston Scientific | 2 | $28 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,619 in reported general payments places this provider in the 85th percentile of 77 gastroenterology providers in District of Columbia.
See all gastroenterology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi On-BodyRisankizumab-Rzaa | 28 | $554,253 |
| StelaraUstekinumab | 21 | $526,563 |
| Humira(Cf) PenAdalimumab | 20 | $416,937 |
| EntyvioVedolizumab | 16 | $139,179 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 21 | $1,041 |
| LoperamideLoperamide Hcl | 23 | $947 |
| Sodium Chloride0.9 % Sodium Chloride | 73 | $880 |
| Celecoxib | 23 | $692 |
| Pantoprazole Sodium | 15 | $191 |
| Famotidine | 11 | $24 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $22,941 | $526,56321 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio | $740 | $139,17916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 77 gastroenterology providers in District of Columbia.
Other gastroenterology in Washington
- James LewisWashington$1M
- John HoganWashington$354K
- Mark MattarWashington$349K
- Jessica KormanWashington$171K
- Mitesh PatelWashington$90K
- Sumona BhattacharyaWashington$87K
- Roshan BashirWashington$40K
- Bruce LuxonWashington$37K
- Dominique HowardWashington$29K
- Vijayrama PoreddyWashington$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.